Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential

Area of Science:

• Hematology
• Pediatric Medicine
• Pharmacology

Background:

• Beta-hemoglobinopathies and -thalassemias significantly impact children's survival and quality of life, especially those without transplant donors.
• Current treatments like hydroxyurea show limited efficacy in a subset of patients, necessitating novel therapeutic strategies.
• There is a need for new agents with dual actions or drug combinations to improve outcomes and minimize chemotherapeutic exposure.

Purpose of the Study:

• To explore novel therapeutic candidates for beta-hemoglobinopathies and -thalassemias in children.
• To evaluate the potential of oral therapeutics that induce fetal hemoglobin and stimulate erythropoiesis.
• To investigate combination therapies, such as EPO and hydroxyurea or short-chain fatty acid derivatives (SCFADs), for enhanced efficacy.

Main Methods:

• Review of existing literature on hydroxyurea, EPO, SCFADs, and other agents for hemoglobinopathies.
• Discussion of a new oral therapeutic candidate entering clinical evaluation.
• Consideration of combination therapy strategies and optimal dosing regimens.

Main Results:

• Existing agents like hydroxyurea are effective in 40-70% of patients, but responses are often incomplete.
• New oral therapeutics inducing fetal hemoglobin and erythropoiesis are under clinical investigation.
• Combination therapies, including SCFADs, show potential for additive or synergistic effects.

Conclusions:

• Childhood is an optimal time to introduce new therapies for hemoglobinopathies, particularly non-mutagenic SCFADs.
• Defining patient subsets likely to respond to specific agents or combinations is crucial for successful treatment.
• Collaborative efforts are essential for advancing these therapeutic avenues in pediatric patients.